Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213349) titled 'Daridorexant for Alzheimer Disease Prevention' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Douglas Mental Health University Institute
Condition:
Alzheimer Disease (AD)
Intervention:
Drug: Daridorexant 50 mg
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 7, 2025
Target Sample Size: 240
Countries of Recruitment:
Canada
To know more, visit https://clinicaltrials.gov/st...